Prelude Therapeutics (PRLD) vs Rocket Pharmaceuticals (RCKT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed Rocket Pharmaceuticals (RCKT) over the past year, gaining 173.2% versus a loss of 22.4%. Over five years, PRLD leads with a -76.1% price change compared with -90.6% for RCKT. Prelude Therapeutics is the larger company by market cap ($309.6 million vs $288.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRLD | RCKT |
|---|---|---|
| Share price | $3.88 | $2.63 |
| Market cap | $309.64M | $288.71M |
| 1-day change | +1.31% | +3.75% |
| YTD return | +33.79% | -25.07% |
| 1-year return | +173.24% | -22.42% |
| 5-year return | -76.14% | -90.58% |
| EPS (TTM) | $-0.73 | $-0.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.83 | $5.45 |
| 52-week low | $1.15 | $2.42 |
| Distance from 52-week high | -43.19% | -51.74% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +137.11% | +223.19% |
| Average volume | 479.23K | 1.66M |
| Shares outstanding | 65.08M | 109.77M |
| Employees | 79 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed RCKT by 195.7 percentage points over the past year.
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About Rocket Pharmaceuticals
RCKT stock →Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees
PRLD vs RCKT FAQ
Which is bigger, Prelude Therapeutics or Rocket Pharmaceuticals?
Prelude Therapeutics (PRLD) is larger, with a market capitalization of $309.64M compared with $288.71M for Rocket Pharmaceuticals (RCKT).
Which stock has performed better over the past year, PRLD or RCKT?
PRLD returned +173.24% over the past 12 months, compared with -22.42% for RCKT (price return, excluding dividends). Past performance does not predict future results.
Are Prelude Therapeutics and Rocket Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.